RxDoctor Payments Data

Miranda Iacopelli, NP

Nurse Practitioner · Grand Rapids, MINPI 1144701228

Payments from drug & device makers

$6,695in general payments, 2019–2025

Across 322 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$557
  • AstraZeneca$535
  • Takeda Pharmaceuticals U.S.A., Inc.$483
  • Incyte Corporation$439
  • Genentech USA, Inc.$372
  • Bristol Myers Squibb$363
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$6,50597%
  • Education$1903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,695 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$14,977
Medicare patients
83
Services billed
1,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax17$83,333
EliquisApixaban18$13,935
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$788
Acyclovir29$686
Pantoprazole Sodium34$660
Gabapentin49$501
Hydroxyurea18$499
Oxycodone Hcl18$327
Dexamethasone22$309
Morphine Sulfate ErMorphine Sulfate15$284
Levothyroxine Sodium19$262
Omeprazole14$191
Prednisone31$159
Methylphenidate Hcl12$122
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$276$83,33317 claims
PfizerEliquis$178$13,93518 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$54$26219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →